Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00242827
NCT00242827
Terminated
Phase 2

An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

Cephalon5 sites in 1 countryApril 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMyeloma
DrugsOral CEP-701

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Myeloma
Sponsor
Cephalon
Locations
5
Status
Terminated
Last Updated
13 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients with Advanced Multiple Myeloma.

Detailed Description

An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients with Advanced Multiple Myeloma.

Registry
clinicaltrials.gov
Start Date
April 2006
End Date
May 2007
Last Updated
13 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Cephalon

Eligibility Criteria

Inclusion Criteria

  • •Patients are included in the study if all of the following criteria are met:
  • •Histological and cytological confirmation of stage II or III multiple myeloma.
  • •Relapsed or primary refractory multiple myeloma, after 1 or more courses of standard therapy, and progressive disease.
  • •ECOG performance status of 0-
  • •Measurable disease as defined by serum M protein of more than 1.0 gm/dl, serum light chain of more than 200 mg/dL, or Bence-Jones proteinuria of more than 200mg/24 hours.
  • •At least 18 years of age.
  • •Normal marrow function: ANC\>1.0x10 9/L, platelets\>50X10 9/L An exception is allowed if myelosuppression or thrombocytopenia is secondary to bone marrow plasmacytosis. Growth factor support is allowed.
  • •Normal organ function: bilirubin \<1.5XULN, AST and ALT\<2XULN, serum creatinine \<2.0 mg/dL.
  • •Contraceptive measures during participation as appropriate.
  • •Willing to be able to comply with study procedures and restrictions.

Exclusion Criteria

  • •Patients are excluded from participating in this study if 1 or more of the following criteria are met:
  • •Nonsecretory disease or plasma cell leukemia (defined as \>2000 circulating plasma cells/uL).
  • •More than 4 prior courses if anticancer therapy (bisphosphonates are not considered anticancer therapy for this criterion)
  • •Chemotherapy or radiotherapy within 4 weeks prior to enrollment
  • •Unresolved adverse events or uncontrolled illness that would be likely to interfere with the objectives of the study.
  • •Treatment with an investigational drug within 4 weeks of first day of study treatment
  • •History of second cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free more than 5 years).
  • •Treatment with potent CYP3A4 inhibitors including cyclosporine, clotrimazole, fluconazole, itraconazole, ketoconazole, voriconazole, erythromycin, clarithromycin, and troleandomycin, human immunodeficiency virus (HIV), protease inhibitors, or nefazodone within 1 week (7 days) of the planned 1st day of study treatment.
  • •Currently receiving warfarin.
  • •Clinical diagnosis of active gastrointestinal ulceration of melena or hematemesis in the previous 4 weeks.

Outcomes

Primary Outcomes

Not specified

Study Sites (5)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
A Randomized, Open Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT 3 Activating Mutations - NARelapsed Acute Myeloid Leukaemia (AML) expressing FLT-3 activating mutations.MedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemia
EUCTR2005-002258-23-DECephalon Inc.220
Completed
Phase 2
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential ThrombocytosisPolycythemia VeraEssential Thrombocytosis
NCT00586651Cephalon39
Active, not recruiting
Phase 1
A Randomized, Open Label Study of Oral CEP 701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT 3 Activating Mutations.Estudio abierto aleatorio del fármaco oral CEP-701 administrado consecutivamente con quimioterapia estándar en pacientes que han sufrido recaídas de leucemia mieloide aguda (LMA) mostrando mutaciones asociadas a la actividad del FLT-3Relapsed Acute Myeloid Leukaemia (AML) expressing FLT-3 activating mutations.
EUCTR2005-002258-23-ESCephalon Inc.120
Active, not recruiting
Not Applicable
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating MutationsAcute Myeloid LeukemiaMedDRA version: 14.1Level: PTClassification code 10059034Term: Acute myeloid leukaemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2005-002258-23-ITCEPHALON EUROPE220
Active, not recruiting
Not Applicable
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations - N/A
EUCTR2005-002258-23-SECephalon, Inc.220